Skip to main content

Table 2 Distribution of CYP2D6 genotype, metabolizer phenotype and activity score

From: Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

CYP2D6 genotype

CYP2D6 metabolizer phenotypea

CYP2D6 activity scoreb

All subjects n = 199 N (%)

India n = 3 N (%)

Peru n = 114 N (%)

Thailand n = 82 N (%)

*4/*4

PM

0

1 (0.5)

1 (0.9)

*4/*41

IM

0.5

1 (0.5)

1 (0.9)

*1/*4

IM

1.0

11 (5.5)

8 (7.0)

3 (3.7)

*10/*10

IM

1.0

19 (9.5)

19 (23.2)

*10/*41

IM

1.0

2 (1)

2 (2.4)

*2/*4

IM

1.0

3 (1.5)

3 (2.6)

*41/*41

IM

1.0

2 (1)

2 (2.4)

*1/*10

EM

1.5

15 (7.5)

15 (18.3)

*1/*41

EM

1.5

6 (3)

3 (2.6)

3 (3.7)

*1/*9

EM

1.5

2 (1)

2 (1.8)

*2/*10

EM

1.5

14 (7)

14 (17.1)

*2/*41

EM

1.5

4 (2)

4 (4.9)

*1/*1

EM

2.0

47 (23.6)

35 (30.7)

12 (14.6)

*1/*2

EM

2.0

45 (22.6)

3 (100)

40 (35.1)

2 (2.4)

*2/*2

EM

2.0

27 (13.6)

21 (18.4)

6 (7.3)

  1. aCYP2D6 poor metabolizers (PM), intermediate metabolizers (IM), extensive metabolizers (EM)
  2. bCYP2D6 activity score is the sum of the per-allele scores; a null allele having a score of 0, a deficient allele a score of 0.5 and a normal allele a score of 1 [12]